^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

COMPANY:
Bio-Techne

i
Other names: Lunaphore | ProteinSimple | Cell Biosciences | Bio-Techne Corporation | Techne Corporation | Bio-Techne | Exosome Diagnostics, Inc. | Exosome Diagnostics | R&D Systems, Inc. | Novus Biologicals | Novus Biologicals LLC | Novus Biologicals, LLC | Tocris Bioscience | Tocris | Asuragen | Asuragen, Inc. | Asuragen Inc. | Exosome Diagnostics, Inc | Exosome Diagnostics Inc. | Exosome Diagnostics Inc | Exosome Diagnostics GmbH | R&D Systems Inc. | R&D Systems Inc | R&D Systems, Inc | R&D Systems | Asuragen, Inc | Asuragen Inc | Bio-Techne Corp. | Bio-Techne Corp | Advanced Cell Diagnostics
Related tests:
Evidence

News

1year
Bio-Techne to highlight novel solutions for cancer and carrier screening at AMP 2024 annual meeting & expo (Bio-Techne Press Release)
"Bio-Techne Corporation...today announced its lineup of presentations and activities for the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo, taking place November 19-23 in Vancouver, British Columbia. Asuragen, a Bio-Techne brand, will be exhibiting and showcasing its latest research products for breast cancer monitoring and carrier screening in booth #811."
Clinical data
|
AmplideX® Nanopore Carrier Plus Kit • ExoLution™ Plus cfDNA + exoRNA Isolation Kit • QuantideX® qPCR ESR1 exoMutation Kit
1year
Lunaphore Comet™ platform paves the way for spatial biology adoption in clinical research (Bio-Techne Press Release)
"Bio-Techne Corporation...announced the release of clinically relevant spatial biology data. The data was generated using Bio-Techne's Lunaphore branded end-to-end spatial biology offering, including its complete range of instruments (COMET) and kits that offer high-value solutions for the translational research community...'COMET enables the identification of multiple biomarkers and spatial interactions between different cell types within the TME'...'Its use together with Nucleai's AI spatial biomarker platform in predicting therapy response for patients enrolled in the SECOMBIT1 study, marks the first application of this innovative technology in a clinical trial, representing a significant step toward identifying predictive biomarkers.'..."
Clinical
1year
Lunaphore partners with discovery life sciences to bring innovative spatial biology solutions to clinical research (Bio-Techne Press Release)
"Bio-Techne Corporation...announced that one of its spatial biology brands, Lunaphore, is partnering with Discovery Life Sciences (Discovery) to add Lunaphore COMET™, a best-in-class spatial biology platform, to Discovery's global suite of biospecimen products and specialty lab services supporting customers with clinical research...Discovery's Lunaphore COMET Hyperplex Immunofluorescence Services will facilitate the development of next-generation assays for clinical trials and provide multidimensional spatial biology insights to advance biomarker discovery, patient stratification, and translational medicine."
Licensing / partnership
over1year
Bio-Techne to present at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (Bio-Techne Press Release)
"Bio-Techne Corporation...announced it will showcase its portfolio of cell and gene therapy workflow solutions at the upcoming annual meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 7-11, 2024, in Baltimore, Maryland."
Clinical data
|
RNAscope™ ISH Probe High Risk HPV
over1year
Bio-Techne announces new distribution agreement with Thermo Fisher Scientific (Bio-Techne Press Release)
"Bio-Techne Corporation...is pleased to announce a significant milestone in its commitment to providing cutting-edge solutions to its customers. Effective May 1, 2024, Bio-Techne will enter into a strategic distribution agreement with Thermo Fisher Scientific, a leading provider of laboratory products and services, in Europe."
Licensing / partnership
over1year
Bio-Techne files patent infringement lawsuit against molecular instruments (Bio-Techne Press Release)
"Bio-Techne Corporation...announced that it has taken legal action in the Unified Patent Court in Europe to halt the infringement of its patented RNAscope® ISH technology by Molecular Instruments, Inc."
Patent • Corporate lawsuit
|
RNAscope™ ISH Probe High Risk HPV
over1year
Bio-Techne surpasses 10,000 peer-reviewed publications citing RNAscope technology (Bio-Techne Press Release)
"Bio-Techne Corporation...announced that Advanced Cell Diagnostics (ACD), part of Bio-Techne's spatial biology division, has surpassed 10,000 peer-reviewed publications referencing the use and application of RNAscope™ ISH technology."
Clinical data
|
RNAscope™ ISH Probe High Risk HPV
over1year
BIO-TECHNE TO PRESENT AT THE 2024 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) CONFERENCE (PRNewswire)
"Bio-Techne Corporation...announced it will showcase its portfolio of solutions to advance cancer research from target discovery to cell therapy development at the upcoming annual meeting of the American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, California. Bio-Techne will showcase its solutions at booth #541, featuring our market-leading portfolio of high-grade life science reagents, immunoassays, automated proteomic analytical instruments, and multiomics solutions that are enabling new drug discovery research, accelerating immune cell therapy, and supporting the development of better diagnostic tools. We will also be debuting our Journey into the Tumor Microenvironment video experience in our booth this year."
Clinical data • Clinical
over1year
BIO-TECHNE RECEIVES EUROPEAN IVDR CERTIFICATION FOR DIAGNOSTIC TEST TO MONITOR CHRONIC MYELOID LEUKEMIA (PRNewswire)
"Bio-Techne Corporation...has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation (IVDR) for its QuantideX qPCR BCR-ABL IS Kit. Previously, the kit was CE-IVD marked for sale in the EU in compliance with the In Vitro Diagnostic Directive (IVDD), which has now been replaced by the IVDR."
European regulatory
|
Quantidex qPCR BCR-ABL IS Kit
almost2years
Bio-Techne's Advanced Cell Diagnostics (ACD) sets new standard in spatial biology with protease-free RNAscope multiomics (Bio-Techne Press Release)
"Bio-Techne Corporation...announced that Advanced Cell Diagnostics (ACD), a Bio-Techne spatial biology brand, has set a new standard with the development of a next-generation, protease-free RNAscope spatial multiomics workflow. Optimized for same-slide detection of protein and RNA biomarkers with unparalleled sensitivity and tissue morphology, the newly developed RNAscope spatial multiomics workflow is compatible with both manual and automated assays. ACD's novel protease-free RNAscope workflow is incorporated in Bio-Techne's recently announced best-in-class multiomics application on Lunaphore's COMET platform."
Clinical
almost2years
Lunaphore and SIB awarded Innosuisse funding to develop innovative AI-based assay development tools (Bio-Techne Press Release)
"Bio-Techne Corporation...announced that Lunaphore, a Bio-Techne brand, and SIB Swiss Institute of Bioinformatics, have been awarded Innosuisse funding for an innovation project. The collaboration aims to develop novel AI-based assay development tools for spatial biology on Lunaphore's COMET™ to further accelerate the adoption of multiplex sequential immunofluorescence (seqIF™) technology in research...Spatial biology utilizes detailed tissue analysis and intracellular interactions to enable profound insights in cancer biology, immuno-oncology, and other research fields."
Financing
2years
Asuragen to present novel clinical testing data at AMP 2023 conference (Bio-Techne Press Release)
"Bio-Techne Corporation...announced that Asuragen, a Bio-Techne brand, will present new data on clinical laboratory testing solutions related to...cancer monitoring, resolving conventionally inaccessible, disease-causing genes, and more at the upcoming meeting of the Association for Molecular Pathology (AMP), to be held November 14-18 in Salt Lake City, Utah."
Clinical data